Baird analyst Colleen Kusy raised the firm’s price target on Oculis (OCS) to $41 from $37 and keeps an Outperform rating on the shares. The firm updated it model following Q4 results which showed programs for DME, AON, and Dry Eye are progressing.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target raised to $32 from $31 at BofA
- Oculis price target lowered to $29 from $30 at H.C. Wainwright
- Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions
- Oculis Holding AG Reports 2024 Financial Results
- Oculis Holding’s Promising Ophthalmology Portfolio and Financial Stability Lead to Buy Rating